ReviewFrontiers in pharmacology2014
Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges.
Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Cerebral iron deposition in the Globus pallidus and Substantia nigra of aging dogs and cats presenting as bilateral hypointensity on T2w and iron-sensitive MRI sequences (SWI, T2*).Frontiers in veterinary science · 2026Article
- Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Impact of trainability on telomere dynamics of pet dogs (Canis lupus familiaris): An explorative study in aging dogs.PloS one · 2025Article
- Case Report: Ischemic brain infarction and cognitive dysfunction syndrome in an aged dog.Frontiers in veterinary science · 2025Article
- Potential revival of cholinesterase inhibitors as drugs in veterinary medicine.Frontiers in veterinary science · 2023Review
- Sphingolipids and DHA Improve Cognitive Deficits in Aged Beagle Dogs.Frontiers in veterinary science · 2022Article
- Comparison of Gut Microbiota of 96 Healthy Dogs by Individual Traits: Breed, Age, and Body Condition Score.Animals : an open access journal from MDPI · 2021Article
- Effects of a Nutritional Supplement on Cognitive Function in Aged Dogs and on Synaptic Function of Primary Cultured Neurons.Animals : an open access journal from MDPI · 2019Article
- The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review.Frontiers in aging neuroscience · 2019Review
- Effect of Age and Dietary Intervention on Discrimination Learning in Pet Dogs.Frontiers in psychology · 2018Article
- Cognitive Aging in Dogs.Gerontology · 2018Review
- Alzheimer's disease: experimental models and reality.Acta neuropathologica · 2017Review
- Oxidative Stress and Protein Quality Control Systems in the Aged Canine Brain as a Model for Human Neurodegenerative Disorders.Oxidative medicine and cellular longevity · 2015Review
- Preclinical and clinical issues in Alzheimer's disease drug research and development.Frontiers in pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Aged dogs spontaneously develop many features of human aging and Alzheimer's disease (AD) including cognitive decline and neuropathology. In this review, we discuss age-dependent learning tasks, memory tasks, and functional measures that can be used in aged dogs for sensitive treatment outcome measures. Neuropathology that is linked to cognitive decline is described along with examples of treatment studies that show reduced neuropathology in aging dogs (dietary manipulations, behavioral enrichment, immunotherapy, and statins). Studies in canine show that multi-targeted approaches may be more beneficial than single pathway manipulations (e.g., antioxidants combined with behavioral enrichment). Aging canine studies show good predictive validity for human clinical trials outcomes (e.g., immunotherapy) and several interventions tested in dogs strongly support a prevention approach (e.g., immunotherapy and statins). Further, dogs are ideally suited for prevention studies as they the age because onset of cognitive decline and neuropathology strongly support longitudinal interventions that can be completed within a 3-5 year period. Disadvantages to using the canine model are that they lengthy, use labor-intensive comprehensive cognitive testing, and involve costly housing (almost as high as that of non-human primates). However, overall, using the dog as a preclinical model for testing preventive approaches for AD may complement work in rodents and non-human primates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.